ImmunityBio (IBRX) Non-Current Deffered Revenue (2014 - 2018)

ImmunityBio (IBRX) has 5 years of Non-Current Deffered Revenue data on file, last reported at $2.7 million in Q4 2018.

• Non-Current Deffered Revenue for Q4 2018 came in at $2.7 million, down 17.62% year-over-year; the trailing twelve-month figure through Dec 2018 was $2.7 million (down 17.62% YoY), and the FY2018 annual result was $2.7 million, down 17.62% from the prior year.
• Non-Current Deffered Revenue slipped to $2.7 million in Q4 2018 per IBRX's latest filing, from $2.9 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $3.6 million in Q2 2017 and troughed at $3000.0 in Q2 2015.
• A 5-year average of $1.7 million and a median of $1.5 million in 2014 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2015 and 2016: Non-Current Deffered Revenue slumped 56.24% in 2015, then jumped 6466.67% in 2016.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $521000.0 in 2014, then slumped by 56.24% to $228000.0 in 2015, then dropped by 17.98% to $187000.0 in 2016, then jumped by 1678.07% to $3.3 million in 2017, then retreated by 17.62% to $2.7 million in 2018.
• Business Quant data shows IBRX's Non-Current Deffered Revenue at $2.7 million in Q4 2018, $2.9 million in Q3 2018, and $3.0 million in Q2 2018.